ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Context Therapeutics (CNTX)
Context Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$0.23▼ -3.50%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Context Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Context Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Context Therapeutics a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $0.20 and $0.26; in 9 out of 10, between $0.16 and $0.33. Estimated annual volatility is 74%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $28.5M
- 52-week high
- $3.62
- 52-week low
- $0.22
- Revenue (12 months)
- $0.0M
- Return on equity
- -76.1%
- Free cash flow (12 months)
- $-31.5M
- Beta
- 1.69
What this means
ATLAS does not publish a fair value for CNTX right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks CNTX has traded between $0.22 and $3.62. Today it is 93.6% below that high and 5% above its low.
Its beta is 1.69: it tends to move more than the market, both up and down.
About the company
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers.
Want to see everything about Context Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Context Therapeutics do?
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers.
What is the chance CNTX goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, CNTX ends the month between $0.20 and $0.26.
How big is Context Therapeutics and what is its P/E ratio?
Context Therapeutics's market capitalization is $28.5M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is CNTX?
ATLAS estimates annual volatility at 74%. In a typical month, half of the outcomes end between $0.20 and $0.26.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer